Señales en vivo de AYLA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 ene 2023 @ 15:56):

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers...

Stats
Volumen de hoy	137 793
Volumen promedio	50 544.00
Capitalización de mercado	0.00
EPS	$0 ( 2023-03-27 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0760 (15.09%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-18	Martell Bridget A	Buy	0
2023-10-18	Orbach Pini	Buy	0
2023-10-18	Golan Roy	Buy	0
2023-01-19	Amoon Growth Fund Limited Partnership	Sell	2 991 473	Common Stock
2023-01-19	Sidransky David	Sell	12 500	Stock Option (right to buy)

INSIDER POWER
-97.96
Last 84 transactions
Buy: 4 327 382 \| Sell: 8 482 924

Volumen Correlación

Largo: 0.26 (neutral)

Corto: -0.81 (strong negative)

Signal:(50.563) Neutral

Ayala Pharmaceuticals Inc Correlación

10 Correlaciones Más Positivas
SPCB	0.933
MERC	0.928
ATER	0.927
YELL	0.923
SISI	0.922
CSSE	0.922
VCSA	0.921
VVOS	0.917
EVOK	0.916
PASG	0.915

10 Correlaciones Más Negativas
SGII	-0.914
SCPL	-0.914
HEES	-0.91
JMPNZ	-0.907
SGEN	-0.904
MSDA	-0.902
THCP	-0.901
TIOAU	-0.899
ROC	-0.899
CSWI	-0.897

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ayala Pharmaceuticals Inc Correlación - Moneda/Commodity

-0.81
( strong negative )

-0.82
( strong negative )

0.00
( neutral )

-0.69
( moderate negative )

-0.71
( moderate negative )

0.52
( weak )

Ayala Pharmaceuticals Inc Finanzas

Annual	2022
Ingresos:	$692 000
Beneficio Bruto:	$90 000.00 (13.01 %)
EPS:	$-2.46

FY	2022
Ingresos:	$692 000
Beneficio Bruto:	$90 000.00 (13.01 %)
EPS:	$-2.46

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$-3.51M (0.00 %)
EPS:	$-4.69

FY	2020
Ingresos:	$3.71M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-3.06

Financial Reports:

No articles found.

Ayala Pharmaceuticals Inc

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.